zilongwang/ReadingBank huggingface dataset:
CHAPTER 410 EMPLOYEE DEVELOPMENT AND TRAINING Section 6. General Provisions 6-1. PURPOSE. The purpose of this policy is to provide information and guidance on training and development opportunities and assign responsibilities for career development and training programs for the Bureau of Engraving and Printing (Bureau/BEP). 6-2. SCOPE. This chapter applies to all employees of the BEP. 6-3. SUPERSESSION. This policy supersedes the following: a. Bureau Personnel Manual, Chapter 410, Section 6, “General Provisions”, April 16, 2010. b. Circular No. 63-00.17, “Procedures for Submitting Non-Duty or Training Requests.” c. Circular No. 64-00.15, “Individual Development Plans.” 6-4. AUTHORITY. This policy is written in accordance with the authority contained in: a. , Public Law 85-507. , Title 5, United States Code (USC), “Training.” , 5 USC, “Merit System Principles.” Chapter 57, 5 USC, , “Payment of Expenses to Obtain Professional Credentials.” , Title 5, Code of Federal Regulations (CFR), “Training.” , Title 5, CFR, “Executive, Management, and Supervisor Development.” g. , as amended by EO 12107, providing for the further training of Government employees through interagency training programs. EO 11895, Delegating Authority of the President to Designate Individuals Appointed by the President to Receive Training.
4.0 Our project aimed to provide Lincoln Laboratory with a basis for further development of the CyberQuad platform. As such, we tested our designs and implementations to determine their feasibility in future applications. Each element of the project - the interface, the localization scheme, and the documentation - provided useful information for use by future developers. This chapter presents all measureable data collected over the course of the project, as well as some analysis, to demonstrate the effectiveness of the features implemented during this project and to provide documentation for future endeavors. 4.1 PC The major section of this project was the development of the UAV adapter system that allowed for PC communication to and control of the CyberQuad. All testing performed in this section primarily involved analysis of this communication to and from the quadrotor. We measured the connection strength, speed, and robustness. This section also involves an evaluation of the performance of the various nodes created over the course of the project. 4.1.1 The purpose of this ROS node was to provide future developers with a tool provides a metric for how well the computer is communicating with the CyberQuad hardware. This would provide them with a general sense of which maneuvers are possible (complex versus simple actions) given a certain level of degraded control and communication. If this information was not taken into consideration, poor link conditions could potentially cause too many missed commands and a poor reaction time, potentially leading to a disastrous result.
2018 Carpool List Emma Kash – Sophie Kash Cathy Meehan – Delaney Smith Olivia Bechstein – Maura Fitzgerald Grace Norgle – Molly Norgle, Leah Coffey Megan Dobrolinsky – Jannette Kazlaukas, Tabitha Torres Caitlin Walsh – Isabel Duffy Caroline Bourjaily – Sara Swanson Mary Catherine Craig – Grace Richards Jillian Devine – Kaili Marriott Rachael Josepher – Julia Josepher Fiona Moran – Jacqueline Yap Mairead Van Santan – Mia Huerta Shannon McGlynn – Amelia Wheaton Caroline Canfield – Carolyn Hicks Erin Edwards – Ryan O’Malley Hannah Janecek – Faith Reynolds Paige Smith Mackenzie Keating Genevieve Giannetti
RESIDENTIAL ACCOMMODATION DIVISION:- Bere Forest – 3 venues plus 1 limited use venue Christchurch Church Scout and Guide Hut London Road, Widley, PO6 3BN SUITABILITY:- Sleepovers, maximum 2 nights, all sections. Max No 25 members 10 leaders. CONTACT:- Elaine 02392 343247 e-mail – 72nd HALL KITCHEN TOILETS/SHOWER AMENIIETIES 1 Large hall for sleeping, dining and activities. (need to stack bedding for day use. Good heating, lighting and natural light. 2 Small hall use as leaders room and first aid. Heating and lighting good. Good size kitchen for 6 people. Safe hot water supply 2 sinks ( 1 at lower level) Electric hob and oven Under work top storage Microwave urn, plates,bowls,cups,cutlery. Female toilets 2 Washbasin 1 Male toilets 2 Washbasin 1 Disabled Toilet with washbasin Close to hall and has night light Car Park outdoor cooking area and campfire circle. Wood collected locally. Historical Church next door. Bus route into Portsmouth.
Waterlooville Guide Centre Walton Court, Waterlooville. SUITABILITY: Sleepovers max stay 36 hours, all sections. Max No 24 members 6 leaders. CONTACT: Liz Linkins 02392 641856 e-mail HALL KITCHEN TOILET/SHOWER AMENITIES 1 Large hall for sleeping dining and activities(need to stack bedding for day use). Good heating and lighting. 2nd hall small use as leaders room and first aid base. Heating and lighting good. Good size kitchen entrance off the main hall. 1 sink clear work surfaces with some storage. Fridge and microwave plenty of power points, cutlery, crockery, mugs and range of pots and pans. Good hot water supply and large domestic range cooker. 1 female toilet cubicle and separate shower cubicle (shower not yet in use) 1 unisex toilet 1 disabled toilet Washbasin in each cubicle. Close to main hall sensory lighting. No outside space and fencing needs repair. Good security Shops 10 minute walk. Car Park
Sundridge Court Nursing home Bereavement Information on Bereavement Most people will experience bereavement at some time in their life. Everyone reacts to their loss in their own unique way. Grief can be very painful and may give rise to feelings and thoughts that you don’t expect. You may find the information in this leaflet helpful. Grieving for someone close The death of someone close can sometimes seem like the most painful thing that has ever happened to you. It can feel bewildering and perhaps frightening. Grief is a natural reaction to loss. There is no right or wrong way to grieve. Most people will experience similar feelings – initial shock and disbelief, perhaps numbness, through to periods of utter confusion, intense pain and questioning. There may be anger, regrets, searching for the person who has died and feeling very alone. Sometimes you may feel very overwhelmed and at times more in control and able to get on with day to day activities. Grieving is not usually a smooth process; it takes time to adjust gradually to life without the person who has died. Feelings, thoughts and experiences Even if you know someone is going to die, it is still a shock when it actually happens, and you may have trouble believing they won’t be coming back. You might dream about them or even think you see the person again. It may take time for you to make an emotional adjustment to the knowledge that they have died. Grief can bring up powerful and unexpected feelings and thoughts, and you may feel overwhelmed at times. It is not unusual to feel angry – anger with the person who has died, anger at the loneliness you feel, or anger at God or the world. Feelings of guilt and regret are common too. These feelings usually lessen with time. This is a usual part of the grieving process. You may find it difficult to concentrate and your thoughts may be confused. Grief can be very tiring so it is
E = EXTRA HELP FROM SPECIALIST SUPPORT RECOMMENDED High risk (score 10 or more) Encourage the person to contact a specialist health care professional eg, GP, counsellor or hospice bereavement service Give a copy of your bereavement brochure support agencies Information Contact details Each organisation to personalise to its local area Specialist bereavement support Information Contact details
established event within the local community for families and friends of people who have been cared for by Accord. Prince and Princess of Wales Hospice All training programmes are currently free of charge at the PPWH. 1. A Loss Grief and Bereavement session is delivered in both the “Palliative care in the care home setting” and “symptom assessment and management in palliative care” module which run twice a year. 2. A Loss, Grief and Bereavement study day is run twice a year. 3. The education and family support team co-facilitate an annual study day for teachers in the Glasgow area on a whole school approach to loss, grief and bereavement and are currently planning a similar event for East Renfrewshire schools. 4. A Loss, Grief and Bereavement session is delivered in a 2 day course on palliative care for Health Care Assistants which runs annually. 5. Sessions were delivered last year to various social care staff and these are planned again for later in the year. 6. Loss, grief and bereavement bespoke training offered to Youth Worker in North of City through Health Improvement Teams. Spiritual support provided to all day service and ward patients and their families. One to one and counselling support provided to all patients, carers, family members and those who are bereaved. This can take place in Hospice or at home. Bereavement drop in – monthly drop in for who are recently bereaved. Bereavement groups – variety of groups run throughout the year for those who are bereaved. Carers Drop in and Art for Carers – runs last Tuesday of every month for carers. Butterfly Service – offer one to one pre and post bereavement support for children and young people affected by life limiting conditions. We also offer bereavement groups and are soon to expand our service to include a variety of supports such as – family days; kinship carers group; parents group; dads group;
stroke A stroke is a brain attack. It happens when the blood supply to part of the brain is cut off, killing brain cells. There are two main types of stroke. The most common type of stroke is due to a blocked blood vessel in the brain. This is called an ischaemic stroke, sometimes referred to as a clot. About 85% of strokes are ischaemic. A stroke due to bleeding in or around the brain is called a haemorrhagic stroke. This is often called a bleed, and is sometimes called a brain haemorrhage. About 15% of strokes are haemorrhagic. There are more than 100,000 strokes a year in the UK. It is the fourth single leading cause of death in the UK, and around one in eight strokes are fatal within the first 30 days. Why stroke can lead to death When someone does not survive a stroke, it is usually due to severe brain injury affecting those parts of the brain that control
Bereavement Support for Children & Young People Organisation Who? When Telephone Website/Email Winston’s Wish Support for children, young people & families Mon-Fri: 9am-5pm (except bank holidays) & Wed evenings 7pm - 9.30pm 0808-8020021 Email: Jigsaw4u (south east) Support for children, young people & families living in Surrey Mon-Fri: 9am - 5pm O208 687 1384 01342-313895 Website: Email: Grief Encounter Support for children and their families Mon-Fri: 9am - 5pm 0208-3718455 Website: Email: Hope Again (Cruse Bereavement Care) Support for bereaved Young People Mon-Fri: 9.30am - 5pm 0808-808 1677 Website: Email: Seeds of Hope Garden based at Cathedral Helps children & young people with loss Open 7 days per week Telephone to arrange a Visit Website: Email: Bereavement Support for Parents/Carers Organisation Who? When Telephone Website/Email
Child Bereavement Parents/Carers Relatives/Siblings Mon-Fri: 9am-5pm 0800-0288840 Website: Email: Child Death Helpline Anyone affected by the death of a child of any age and from any cause Every eve: 7pm-10pm Mon-Fri: 10am-1pm + Tues&Wed: 1pm - 4pm 0800-282986 or 0808-8006019 (if calling from mobile) Website Email: The Compassionate Friends For bereaved parents and their families Daily: 10-4pm & Phone always answered by a bereaved parent 0345-1232304 Website: Email: The Lullaby Trust Support & advice following the sudden death of an infant Mon-Fri: 10am-5pm Sat/Sun & Public holidays:6pm-10pm 0808-8026868 Website: Email: Bliss Support following death of a premature baby Mon-Wed: 10am-12 noon & 7pm-9pm Thurs & Fri: 0808-8010322 Website: Email: SANDS Support following death of a baby Mon-Fri: 9.30-5.30pm +Tues/Thurs: 6 -10pm 0808-1643332 Website: Email: SOBS (Survivors of Bereavement by Suicide) Support for those bereaved by suicide Every day 9am-9pm 0300-111 5065 Website: uk-sobs.org.uk/ Email: Surrey branch: Cruse Bereavement Care Adults affected by death Mon-Fri: 9.30am-5pm Tues/Wed/Thur:til 8pm 0808-8081677 Website: Email: Cruse Heath & Waverley Answerphone available 01483-565660 Website:
Email: Cruse South Answerphone available 01737-772834 Website: Email: Cruse Epsom, Answerphone available 0208-3937238 Website: Email: Cruse North Answerphone available 01932-571177 Website: Email: Care for the Family: Bereaved Parent Support Support following loss of a child Mon:9.30-5pm Tues-Thurs: 9-5pm Fri: 9-4.30pm 029-2081 0800 Website: Email:
Bereavement Support for Parents/Carers Organisation Who? When Telephone Website/Email Child Bereavement Parents/Carers Relatives/Siblings Mon-Fri: 9am-5pm 0800-0288840 Website: Email: Child Death Helpline Anyone affected by the death of a child of any age and from any cause Every eve: 7pm-10pm Mon-Fri: 10am-1pm + Tues&Wed: 1pm - 4pm 0800-282986 or 0808-8006019 (if calling from mobile) Website Email: The Compassionate Friends For bereaved parents and their families Daily: 10-4pm & Phone always answered by a bereaved parent 0345-1232304 Website: Email: The Lullaby Trust Support & advice following the sudden death of an infant Mon-Fri: 10am-5pm Sat/Sun & Public holidays:6pm-10pm 0808-8026868 Website: Email: Bliss Support following death of a premature baby Mon-Wed: 10am-12 noon & 7pm-9pm Thurs & Fri: 0808-8010322 Website: Support following of a baby Mon-Fri: 9.30-5.30pm +Tues/Thurs: 6 -10pm 0808-1643332 Website: Email: SOBS (Survivors of Bereavement by Suicide) Support for those bereaved by suicide Every day 9am-9pm 0300-111 5065 Website: uk-sobs.org.uk/ Email: Surrey branch:
Bereavement Care Adults affected by death Mon-Fri: 9.30am-5pm Tues/Wed/Thur:til 8pm 0808-8081677 Website: Email: Cruse Heath & Waverley Answerphone available 01483-565660 Website: Email: Cruse South Answerphone available 01737-772834 Website: Email: Cruse Epsom, Answerphone available 0208-3937238 Website: Email: Cruse North Answerphone available 01932-571177 Website: Email: Care for the Family: Bereaved Parent Support Support following loss of a child Mon:9.30-5pm Tues-Thurs: 9-5pm Fri: 9-4.30pm 029-2081 0800 Website: Email: Bereavement Support for Children & People Organisation Who? When Telephone Website/Email Winston’s Wish Support for children, young people & families Mon-Fri: 9am-5pm (except bank holidays) & Wed evenings 7pm - 9.30pm 0808-8020021 Email:
Jigsaw4u (south east) Support for children, young people & families living in Surrey Mon-Fri: 9am - 5pm O208 687 1384 01342-313895 Website: Email: Grief Encounter Support for children and their families Mon-Fri: 9am - 5pm 0208-3718455 Website: Email: Hope Again (Cruse Bereavement Care) Support for bereaved Young People Mon-Fri: 9.30am - 5pm 0808-808 1677 Website: Email: Seeds of Hope Garden based at Cathedral Helps children & young people with loss Open 7 days per week 01483-547880 Telephone to arrange a Visit Website: Email:
Special Innovation Project Health Information Technology for Post Acute Care Stratis Health was selected to lead the Centers for Medicare & Medicaid Services' Special Innovation Project: Health Information Technology for Post-Acute Care Providers (HITPAC). This project will assist post acute care providers in Minnesota—focusing on skilled nursing facilities—to improve quality and coordination of care through the effective use of health information technology (HIT) during care transitions, leverage standardized patient assessment content to facilitate health information exchange with hospitals, and reduce medical errors by improving the medication management process. Across Minnesota, two-three communities, each with at least five nursing homes and one referral hospital, are expected to participate in this post acute care HIT project. Within these communities, nursing homes will collaborate with a referral hospital to exchange standardized patient assessment content, discharge documents, and other information. The hospitals will provide updated information to community nursing homes at the transfer of care. HITPAC shall focus on improving patient care in the post acute care setting using Health IT to support the exchange of health information at times of transitions in care or to support instances of shared care involving multiple members of the care team. Specifically, this Special Innovation Project (SIP) shall focus on the use of interoperable health information exchange applications that use standardized patient assessment content, electronic prescribing (eRx), medication reconciliation, and/or electronic medication administration record (eMAR). Key collaborators on the project will be the Minnesota Hospital Association, Care Providers of Minnesota, Aging Services of Minnesota, the Minnesota Department of Health, Minnesota Alliance for Patient Safety, CHIC (Community Health Information Collaborative), and the LeadingAge/Center for Aging Services Technology. Stratis Health will Participating organization will Provide a qualified team of staff to lead and support the project Create a multidisciplinary team committed to the aims of the project and to working with Stratis Health Designate a primary contact, who will have expertise and ready access to best practices, resources, and tools Designate one person who, in a leadership capacity, can drive and support the organization’s efforts and serve as the Stratis Health contact Obtain endorsement from its CEO, and Quality Director
Benevolence Request Form Date:_____________ Name of Person(s) Requesting: __________________________________ Current Address: ______________________________________________ City: ______________________ State: _______ Zip Code: __________ Current Phone/Contact Person: __________________________________ Type of Need Requested: Reason for Request: ***My signature guarantees the information provided above is accurate and true. I also understand that benevolence from this church is a one-time gift and cannot for another request for a period of _____ months. ***All requests must have photo ID. _________________________________ ________________ Signature of Person/Persons Requesting Date Services Provided? _________ If not provided, reason for declining: ________________________________________ Copyright © 2015 Pastoral Care Inc. All Rights Reserved. All material is intended for individual use only. Any other use, such as distribution, promoting one's ministry or adding to websites, is prohibited unless written permission granted by Pastoral Care Inc.
BETWEEN FAMILY BUSINESS CHARACTER AND TERRITORIAL IDENTITY MAJOCCHI, ANTONIO JEAN FRANCOIS HENNART EMANUELE FORLANI EUROPEAN DIFFERENCES IN THE EXTENT OF FAMILY FIRMS INTERNATIONALIZATION Saturday S13 / SATURDAY: 10,00-11,30 – Chair: Leona Achtenhagen Author Co-authors Title HERNÁNDEZ, REMEDIOS SOUMODIP SARKAR, Mª CONCEPCIÓN THE FAMILY BUSINESS DEFINITION UNDER THE MICROSCOPE- WHAT IS ITS ESSENCE? HOWORTH, CAROLE NICK ROBINSON OUR FAMILY AND OTHER ANIMALS, IN AND OUT OF BUSINESS RAMIREZ-PASILLAS, MARCELA BRUNDIN, LEIF MELIN FAMILY MINDSETS, PROACTIVENESS AND COMPETITIVE AGGRESSIVENESS IN FAMILY BUSINESSES S14 / SATURDAY: 10,00-11,30 – Chair: Daniela Montemerlo Author Co-authors Title BROEKAERT, WOUTER BART HENSSEN, LAMBRECHT THE ROLE OF PSYCHOLOGICAL OWNERSHIP DURING CHANGE PROCESSES IN FAMILY BUSINESSES: TOWARDS AN INTEGRATED MODEL AND FUTURE RESEARCH DIRECTIONS FERANITA, FERANITA THE DESIGN AND USE OF MANAGEMENT CONTROL SYSTEMS IN FAMILY BUSINESS KOLADKIEWICZ, IZABELA FAMILY MEETINGS AS A MECHANISM FOR FAMILY GOVERNANCE: A REVIEW OF EXPERIENCES S15 / SATURDAY: 10,00-11,30 – Chair: Giovanna Campopiano Author Co-authors Title UHLANER, LORRAINE MARTA BERENT-BRAUN KIMBERLY EDDLESTON ROBERTO H. FLÖREN PREDICTORS OF SME’S ENVIRONMENTALLY RESPONSIBLE BEHAVIOR: DIFFERENCES BETWEEN FAMILY AND NONFAMILY BUSINESSES CAMPS MARTIN, SUSANNA SHARON M. PILAR MARQUES SOCIAL CAPITAL AND FAMILY BUSINESS:ANALYZING STOCKS AND FLOWS UNDER THE LOGIC OF DECISION COMMUNICATION
Pub Crawl – next event Kay Street Krawl Auxiliary will be doing raffle during convention Discussed Amazon for additional donation Other - Kevin discussed different ways Election of Foundation Officers for 2017 (Directors board will appoint the foundation officers per Article IV of the foundation bylaws for the 2017 year. a. President – Kevin O’Meara b. CFO – Art Smith c. Secretary – Chuck Carroll Motion by Steve Hartman to leave officers in place, 2nd by Michelle Cannady, passed unanimously. Other New business Webmaster – having problems with commitment. It was free, but now looking at options to a new server and new webmaster NOLB also maintains website Old Business Conflict of Interest Statements provided to 2017 Foundation Officers present Open Discussion – Jake Duran requested a list of money donated to outside organizations and other locals. Donated to Ft. McMurray in Canada to firefighters who lost their home. Meeting Adjourned—1514 hours Respectfully Submitted By, Chuck Carroll Secretary CDF Firefighters Local 2881 Benevolent Foundation cc: Foundation Board “A” Members “B” Member CAL FIRE 2881 Executive Board
Tables Table 1: Boolean search terms utilized for individual patent and publication cluster search Urology OR urological OR urologist AND “surgery” OR “surgeon” AND “image guidance” OR “image guided” OR “augmented Robotic Urology OR urological OR urologist AND “surgery” OR “surgeon” AND “robot” OR “robotic” OR “daVinci” OR “da Vinci” MIS Urology OR urological OR
urologist AND “surgery” OR “surgeon” AND “minimally invasive” OR “laparoscopic” OR “laparoscopy” OR “minimal access” OR “key hole” Catheters/devices Urology OR urological OR urologist AND “surgery” OR “surgeon” AND "catheter" OR "drain" Laser Urology OR urological OR urologist AND “surgery” OR “surgeon” AND "laser" OR
Fig. S6. Fluorescence spectra of compound 3 (10 M) and HBTPB (10 M) with H2O2 (800 M) in CH3CN/H2O (1/1, v/v, HEPES 10 mM, pH = 7.4). Fig. S7. TLC analysis of dye 3 and the reaction mixture of HBTPB with H2O2 under illumination by 365 nm (left) and 254 nm (right) lights. Spots on the TLC plates are: (a) the reaction mixture of probe HBTPB with H2O2; (b) probe HBTPB; (c) dye 3. Fig. S8. HRMS (ESI+) spectrum of HBTPB in the presence of H2O2. Fig. S9. Cell viability values (%) of A549 cells in the presence of different concentrations of probe HBTPB (0, 0.1, 1.0, 10, 30 and 50 μM) estimated by CCK-8 Fig. S10. 1H NMR spectrum of compound 2 in CDCl3. Fig. S11. NMR spectrum of compound 2 in CDCl3. Fig. S12. HRMS (ESI+) spectrum of compound 2. Fig. S13. 1H NMR spectrum of probe HBTPB in DMSO-d6.
Electronic Supporting Information High photostable, lysosome-targeted BODIPYs with green to emission for lysosome imaging in living cells Zhuo Ye, Chao Xiong, Jian Pan, Dongdong Su*, Lintao Zeng* Tianjin Key Laboratory of Organic Solar Cells and Photochemical Conversion, Tianjin University of Technology, Tianjin 300384, P.R. China. Fax: (+86) 22 60214252; E-mail: (D. Su); (L. Zeng). Contents Figure S1. 1H NMR spectra of Lyso-Green in CDCl3 (400 MHz) P2 Figure S2. 13C NMR spectra of Lyso-Green in CDCl3 (100 MHz) P2 Figure S3. HR MS spectrum of Lyso-Green (ESI) P3 Figure S4. FT-IR spectra of Lyso-Green (KBr pellet) P3 Figure S5. 1H NMR spectra of Lyso-Red in DMSO-d6 (400 MHz) P4 Figure S6. 13C NMR spectra of Lyso-Red in CDCl3 (100 MHz) P4 Figure S7. HR MS spectrum of Lyso-Red (ESI) P5 Figure S8. FT-IR spectra of Lyso-Red (KBr pellet) P5 Figure S9. 1H NMR spectra of Lyso-NIR in DMSO-d6 (500 MHz) P6 Figure S10. 13C NMR spectra of Lyso-NIR in DMSO-d6 (125 MHz) P6 Figure S11. HR MS spectrum of Lyso-NIR (ESI) P7 Figure S12. FT-IR spectra of Lyso-NIR (KBr pellet) P7 Figure S13. Photostability of Lyso-Green, Lyso-Red and Lyso-NIR in EtOH P8 Figure S14. Photostability of Lyso-Green, Lyso-Red and Lyso-NIR in DMSO P8 Figure S15. Photostability of Lyso-Green, Lyso-Red and Lyso-NIR in PBS (20%
DMSO) P9 Figure S16. pH stability and effects of ion interference of Lyso-Green, Lyso-Red, Lyso-NIR P9 Figure S17. Cytotoxicity of Lyso-Green, Lyso-Red and Lyso-NIR P10 Figure S18. Confocal fluorescence images of HeLa cells stained with Lyso-GreenP10 Figure S19. Confocal fluorescence images of HeLa cells stained with Lyso-Red P11 Figure S20. Confocal fluorescence images of HeLa cells stained with Lyso-NIR P11 Figure S1. 1H NMR spectra of Lyso-Green in CDCl3 (400 MHz). Figure S2. 13C NMR spectra of Lyso-Green in CDCl3 (100 MHz). Figure S3. HR MS spectrum of Lyso-Green (ESI). Figure S4. FT-IR spectra of Lyso-Green (KBr pellet). Figure S5. 1H NMR spectra of Lyso-Red in DMSO-d6 (400 MHz). Figure S6. 13C NMR spectra of Lyso-Red in CDCl3 (100 MHz). Figure S7. HR MS spectrum of Lyso-Red (ESI). Figure S8. FT-IR spectra of Lyso-Red (KBr pellet).
Figure S19. Confocal fluorescence images of HeLa cells stained with (a) LysoTracker Green DND-26 (100 nM, λex = 488 nm, λem = 500–530 nm) and (b) Lyso-Red (1 μM, λex = 543 nm, λem = 560–610 nm) at 37 °C for 30 min. (c) Merged image of (a) and (b). (d) Bright field image. (e) Correlation plot of LysoTracker Green DND-26 and Lyso-Red intensities. (f) Intensity profile of regions of interest (ROI) across Hela cells. Scale bar: 25 μm. Figure S20. Confocal fluorescence images of HeLa cells stained with (a) LysoTracker Green DND-26 (100 nM, λex = 488 nm, λem = 500–530 nm) and (b) Lyso-NIR (10 μM, λex = 638 nm, λem = 652–732 nm) at 37 °C for 30 min. (c) Merged image of (a) and (b). (d) Bright field image. (e) Correlation plot of LysoTracker Green DND-26 and Lyso-NIR intensities. (f) Intensity profile of regions of interest (ROI) across Hela cells. Scale bar: 25 μm.
Supporting Information Green Phosphorescent Homoleptic Iridium(III) Complexes for Highly Efficient Organic Light-Emitting Diodes Hee Un Kim,a,† Hea Jung Park,a,† Jae-Ho Jang,a Wook Song,b In Hwan Jung,c Jun Yeob Lee, *,b and Do-Hoon Hwang*,a aDepartment of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan 609-735, Republic of Korea bSchool of Chemical Engineering, Sungkyunkwan University 2066, Jangan-gu, Suwon, Gyeonggi 440-746, Republic of Korea cDepartment of Chemistry, Kookmin University, 77 Jeongneung-ro, Seongbuk-gu, Seoul 02707, Republic of Korea *E-mail: †H.U.K. and H.J.P. contributed equally Figure S1. MALDI-TOF mass spectra of (a) Ir(ppyTMS)3 and (b) Ir(mPppyTMS)3.
Table S1. The correspongding FITR peaks of PEO, ALG-CaCl2, alginate dialdehyde, CMCS-ADA, CMCS-GA Assignments PEO ALG-CaCl2 alginate dialdehyde CMCS-ADA CMCS-GA 840 C-O-C stretching,C-C stretching 964 CH2 rocking,CH2 twisting 1102 C-O-C stretching 1342 CH2 wagging 1414 symmetric stretch -COO- symmetric stretch -COO- symmetric stretch -COO- 1603 antisymmetric stretch -COO- antisymmetric stretch -COO- antisymmetric stretch -COO- 1732 stretching vibration of
Complication Time from Radiotherapy EBRT Dose and Type Concurrent Chemotherapy Brachytherapy Dose and Type Type of Surgery Bladder D2cc Radiation Cystitis – Grade 3 44 months 3D conformal 45Gy in 25 fractions Weekly Cisplatin (40mg/m2) 5.5Gy x 3 fractions, 3D Open 68.3Gy Stress Incontinence – Grade 3 31 months IMRT 45Gy in 25 fractions Weekly Cisplatin (40mg/m2) 5.5Gy x 3 fractions, 3D MRI-based Open 64.4Gy Stress Incontinence – Grade 3 9 months IMRT 45Gy in 25 fractions Weekly Cisplatin (40mg/m2) 5.5Gy x 4 fractions, 3D MRI-based Open 73.0Gy Supplementary Table: Details for Patients with Grade 3+ Radiotherapy Related Complications EBRT = external beam radiotherapy. 3D = 3 dimensional. IMRT = intensity modulated radiotherapy. Gy = Gray. D2cc = dose to 2 cubic centimeters. MRI = magnetic resonance imaging.
Fig. S3. Viability of ATDC5 cells treated with various concentrations of hyaluronate (HA), alginate (AL) and hyaluronate-alginate hybrid (HAH) solutions ([ATDC5] = 1×104 cells/well, 24 h). Table S1. Quantified amount of peptide bound to hyaluronate-alginate hybrid. Peptide/alginate a) (mol/g) HAV/alginate b) (mol/g) % Conjugation RGD/alginate b) (mol/g) % Conjugation 5.25 3.7 70 4.4 84 10.5 9.6 91 9.4 89 21 18.3 87 17.4 83 42 33.0 81 38.0 90 105 83.3 79 81.2 77 a) The amount of peptide used to prepare peptide-modified hyaluronate-alginate hybrid. a) The amount of peptide bound to peptide-modified hyaluronate-alginate hybrid.
S2. Descriptors used in the QSAR modeling NO. Descriptors Unit Selection reasons 1 log D n-octanol/water distribution coefficient cm3/mol Hydrophobic interactions (Bhal et al., 2007; Kah and Brown, 2008; Yang et al., 2013) 2 qH+ the most positive net atomic charge on a hydrogen atom a.c.u. hydrogen bonding electrostatic interactions (Yang et al., 2013, 2017) 3 the most negative net atomic charge on a oxygen atom and its chemical form adjusted descriptor a.c.u. 4 the most negative net atomic charge on a nitrogen atom and its chemical form adjusted descriptor a.c.u. 5 qC+ , qC+ adj the most positive net atomic charge on a carbon atom and its chemical form adjusted descriptor a.c.u. 6 the most negative net atomic charge on a carbon atom and its chemical form adjusted descriptor a.c.u. 7 Vs, max, Vs, max-adj the most positive values of the molecular surface potential and its chemical form adjusted descriptor eV 8 Vs, min, Vs, min-adj the most negative values of the molecular surface potential and its chemical form adjusted descriptor eV 9 Vs- ,Vs--adj the averages of the positive potentials on the molecular surface and its chemical form adjusted descriptor eV 10 Vs+, Vs+-adj the averages of the negative potentials on the molecular surface and its chemical form adjusted descriptor eV 11 Vs,aver the average potentials on the molecular surface eV 12 Π the average deviation of surface potential eV
Yang, X.H., Lyakurwa, F., Xie, H.B., Chen, J.W., Li, X.H., Qiao, X.L., Cai, X.Y., 2017. Different binding mechanisms of neutral and anionic poly-/perfluorinated chemicals to transthyretin revealed by in silico models. Chemosphere 182, 574-583. Yuan, H.D., Ranatung, R., Carr, P.W., Pawliszyn, J., 1999. Determination of equilibrium constant of alkylbenzenes binding to bovine serum albumin by solid phase microextraction. Analyst 124, 1443-1448. Zvinavashe, E., Murk, A.J., Rietjens, I.M., 2008. Promises and pitfalls of quantitative structure-activity relationship approaches for predicting metabolism and toxicity. Chem. Res. Toxicol. 21, 2229-2236.
If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how. ______†______ 10.ǂ MODIFICATIONS see below at page 11 If the intervention was modified during the course of the describe the changes (what, why, when, and how). ______†______ HOW WELL 11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them. see below at page 11 _____________ 12.ǂ Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned. see at page 11 _____________ ** Authors - use N/A if an item is not applicable for the intervention being described. Reviewers – use ‘?’ if information about the element is not reported/not sufficiently reported. † If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL). ǂ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. * This checklist has been used in conjunction with the TIDieR guide (see BMJ 2014;348:g1687) which contains an explanation and elaboration for each item. * The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a randomised is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see ) as an extension of Item 5 of the CONSORT 2010 Statement. When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 Statement (see ). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see ).
19, 3, 44 (superior)# 3.97 .0003 0.823 R – WB FA 3.4 2.3 yrs LTP Kang et al. (2013) Sagittal Stratum –* – < .05 – L – WB AD 5.0 0.0 hrs NOV Tang et al. (2012) All comparisons are for meditators > controls except where indicated by an asterisk (*). AD: axial diffusivity; CT: cortical thickness; FA: fractional anisotropy; CG: cortical gyrification; GMC: gray matter concentration; GMV: gray matter volume; hrs: hours; L: left; LTP: long-term practitioners; NOV: novices; PWT: point-wise thickness; R: right; RD: radial diffusivity; RDS: radial distance; ROI: region of interest; TRV: total region volume; yrs: years; WB: whole-brain. – Data not reported or not applicable * Controls > meditators # Provisional results (either trending toward statistical significance, uncorrected for multiple comparisons, or not fully independent of previous analyses in the same study) ~ t-statistic estimated based on color bar in figures (no exact t-statistic provided)
Supplementary Table 2. Interaction between PM exposures and sex on TL Exposure P-value for interaction a TL PM2.5 (μg/m3) 0.673 Personal EC (μg/m3) 0.360 PM10 (μg/m3) Examination Day 0.297 1 Day 0.670 1-2 Days 0.718 1-5 Days 0.323 1-7 Days 0.341 1-10 Days 0.947 1-14 Days 0.566 a Based on mixed-effects model, the results were adjusted for age, sex, BMI, group, number of cigarettes smoked during examination time, day of the week, usage of central heating, time used for commuting to work and temperature and dew point values.
SI Table S5. Principal component analysis factor loadings (Varimax raw) for surface sediment data sets Factor 1 Factor 2 PFOS 0.804891 0.567781 PFHxS 0.836662 0.469783 FOSA 0.105406 0.918669 PFDoDA 0.437568 0.834486 PFUnDA 0.672795 0.691285 PFDA 0.733867 0.627303 PFNA 0.843793 0.490251 PFOA 0.923521 0.345417 PFHpA 0.904709 0.285011 0.820938 0.219687 PFBA 0.942481 0.138881 Explained variance 6.487228 3.463217 Total proportion 0.589748 0.314838 Variance (%) 80.2 10.2
Bornehag, 2015: MHiNP, MOiNP, MCOP, ∑DiNP (MU) Swan, 2015: MEHP, MEHHP, MEOHP, ∑DEHP ( MU, boys) Swan, 2015: MECPP, MEP, MBzP, MnBP, MiBP, MCPP, MCNP, MCOP (MU); MEHP, MEHHP, MEOHP, ∑DEHP (MU, girls) Cryptorchidism Swan, 2008: MEHP, MEHHP (MU, boys) - Swan, 2008: MEP, MnBP, MMP, MEOHP (MU, boys) Anti-androgenic Lin, 2011: ∑DEHP (MU, girls) Araki, 2014: MEHP (maternal blood, boys) - Lin, 2011: MMP, MEP, MBP, MBzP, MEHP, MEHHP, MEOHP (MU); ∑DEHP (MU, boys) Araki, 2014: MEHP (maternal blood, girls) Comments: In exposure to phthalates and hypospadias and CHD: not yet investigated by nested prospective cohort studies. Abbreviations: AF, amniotic fluid; AGD, anogenital distance; AGI, anogenital index; BW, birth weight; CB, cord blood; CHD, congenital heart defect; HMW-phthalates, high-molecular-weight phthalates; JEM, job-exposure matrix; BW, birth weight; LMW-phthalates, phthalates; MU, maternal urine; ∑DEHP, summed DEHP metabolites (MEHP, MEHHP, MEOHP, MECPP); ∑DiNP, summed DiNP metabolites (MHiNP, MOiNP, MCOP). a all: DEHP, DEP, DMP, DiBP, DnBP, DMEP, BMPP, DEEP, DNHP, BBP, DBEP, DCHP, DNOP, DNP. b maternal exposure defined as occupational exposure and/or newly decorated house. Supplementary 2 Biological matrices used in studies with unfavorable outcomes [First author, year: outcomes (involved metabolites, sex if differences)]. Type of study Cross-sectional Case-control Prospective cohort Risk Increased risk Decreased Increased Decreased Increased Decreased weight
Maternal urine Weinberger, 2014: decreased gestational age - Meeker, 2009a: preterm (MnBP, ∑DEHP) Ferguson, 2014b: preterm (MEHP, MECPP, ∑DEHP, MnBP) Ferguson, 2014a: placental preterm (MECPP, ∑DEHP), spontaneous preterm (MECPP, ∑DEHP, MnBP, MBzP) - Whyatt, 2009: decreased gestational age (MEHP, MEHHP, MEOHP, MECPP) Swan, 2005: decreased AGI (MEP, MnBP, MBzP, MiBP) Swan, 2008: decreased AGD (MEP, MnBP, MMP, MEHP, MEOHP, MEHHP), cryptorchidism (MEHP, MEHHP) Suzuki, 2012: decreased AGD (MEHP) Bustamante-Montes, 2013: decreased AGD (∑(MEHP, MBzP, MEP, MBP)) Lin, 2011: anti-androgenic function (∑DEHP, Bornehag, 2015: decreased AGI (MHiNP, MOiNP, MCOP, ∑DiNP) Swan, 2015: decreased AGD (MEHP, MEHHP, MEOHP, ∑DEHP, boys) Adibi, 2009: preterm, increased gestational age (MEHP, MEHHP, MEOHP) Wolff, 2008: increased gestational age (MEHP, Increased birth length (MBzP) and head circumference MEP) Cord blood Latini, 2003: decreased gestational age (MEHP) 2014: preterm birth (all except DCHP), decreased gestational age (alla), low BW (DEEP), low birth 2010: increased head (MBP) Zhang, 2009: low BW (DnBP, MEHP), low birth length (DEHP, MEHP) - - -
Table S3: Accuracy, precision and 95% confidence intervals of PFASs in NIST SRM 1957 for each sampling group 2001-2004 (70 yr. old) n=56 2006-2009 (75 yr. old) n=54 2011-2014 (80 yr. old) n=46 NIST *Riddell et al. 2009 Analyte mean concentration (ng/mL) mean concentration (ng/mL) mean concentration (ng/mL) reference concentration (ng/mL) mean concentration (95% CI) PFHpA 0.23 (±0.01) 0.27 (±0.01) 0.26 (±0.01) 0.31 (±0.04) N/A PFOA 4.2 (±0.06) 4.6 (±0.12) 4.5 (±0.04) 5.0 (±0.40) N/A PFNA 0.74 (±0.01) 0.81 (±0.02) 0.83 (±0.01) 0.88 (±0.07) N/A PFDA 0.28 (±0.01) 0.28 (±0.01) 0.25 (±0.01) 0.39 (±0.10) N/A PFUnDA 0.18 (±0.03) 0.23 (±0.03) 0.19 (±0.01) 0.17 (±0.03) N/A PFHxS 3.4 (±0.04) 3.6 (±0.09) 3.5 (±0.02) 4.0 (±0.75) N/A L-PFOS 11 (±0.16) 11 (±0.29) 11 (±0.48) N/A 10.6 (±2.86) *PFOS and PFOS isomers were not reported in the NIST reference. Therefore, the linear PFOS isomer (L-PFOS) levels detected in the NIST samples were compared to previously reported independent values (Riddellet al. 2009)
S2. Factors affecting organic contaminants availability in soil and associated measurement Factors Specific Factors References Soil type and characteristics Soil organic matter (SOM) and mineral matter content, structure and texture, cationic exchange capacity, nanoporosity Alexander, 2000; Chung and Alexander, 1998; Chung and Alexander, 2002; Duan et al., 2015a; Hatzinger and Alexander, 1995; Huang et al., 2003; Pignatello and Xing, 1996; Semple et al., 2007 interactions Ageing, diffusion, sorption, desorption, sequestration Alexander, 2000; Braida et al., 2003; Hatzinger and Alexander, 1995; Kastner et contaminant
al., 2014; Kelsey et al., 1997; Lu and Pignatello, 2002; Luthy et al., 1997; Ma et al., 2012b; Pignatello and Xing, 1996; Reid et al., 2000a; Semple et al., 2003; Weber et al., 1998 interactions Rate of uptake, adaptation, toxicity, presence and intrinsic capacity of relevant enzymes, Alexander, 2000; Huang et al., 2003; Juhasz and Naidu, 2000; Semple et al., 2007 Contaminant properties Hydrophobicity, lipophilicity, vapour pressure, ionic and oxidation Couling et al., 2010; Hickman et al., 2008; Juhasz and chemical
potential, Koc, Kow, molecular mass and structure and aqueous solubility 2000; Wilson and Jones, 1993 Presence of contaminants and/or substances Number of applications, concentration, multiple amendment, activated charcoal, black carbon, NAPLs, heavy metals Couling et al., 2010; Dew et al., 2005; Obuekwe and Semple, 2013a, b; Rhodes et al., 2008b; Rhodes et al., 2012 General environmental conditions & loss processes Moisture content, temperature, pH, precipitation, degradation, volatilization, seasonal variations Barraclough et al., 2005; ECETOC, 2010, 2013a, 2013b; Rhodes et al., 2012; Zarfl et al., 2009 Extraction technique used * Cui et al., 2013; ECETOC, 2013a; Ehlers and Laboratory and field conditions* Precision and accuracy of experiment* Sampling robustness*
bioavailability/bioaccessibility of PAHs in soil: fundamentals to application, J. Hazard. Mater. 261 (0), 2013, 687–700. Semple K., Doick K., Wick L. and Harms H., Microbial interactions with organic contaminants in soil: definitions, processes and measurement, Environ. Pollut. 150 (1), 2007, 166–176. Semple K., Morriss A. and Paton G., Bioavailability of hydrophobic organic contaminants in soils: fundamental concepts and techniques for analysis, Eur. J. Soil Sci. 54 (4), 2003, 809–818. Sims R. and Overcash M., Fate of polynuclear aromatic compounds (PNAS) on soil-plant systems, Residue Rev. 88, 1983, 1–68. Weber W.J., Huang W.L. and Yu H., Hysteresis in the sorption and desorption of hydrophobic organic contaminants by soils and sediments — 2. effects of soil organic matter heterogeneity, J. Contam. Hydrol. 31 (1), 1998, 149–165. Wilson S.C. and Jones K.C., Bioremediation of soil contaminated with polynuclear aromatic hydrocarbons (PAHs): a review, Environ. Pollut. 81 (3), 1993, 229–249. Zarfl C., Klasmeier J. and Matthies M., Non-extractable residues are not necessarily bound residues, In: Poster Presented at SETAC Europe 19th Annual Meeting, 2009, Goteborg, Sweden.
Chemical CAS Human Health Effects Aquatic toxicity Environmental fate Acute Toxicity Carcinogenicity Genotoxicity Reproductive Developmental Neurological Repeated Dose Skin Sensitization Respiratory Sensitization Eye Irritation Dermal Irritation Chronic Persistence (Nanocyl NC7000/Baytubes C150P) List number 936-414-1 M L L L L H L L L VL L L H L MWCNT NC7000™ (Transmission electron microscopy; courtesy of Nanocyl SA) CAS No: no List No: 936-414-1 MW: ca 70,000,000 Physical forms: solid Use: flame retardant synergist
In vivo and in vitro (HE-CAM test = Hen's Egg Membrane) studies with other types of MWCNT (long and short) suggest slight irritation (reversible conjunctival redness and discharge) not warranting classification or no irritating effect. In an in vivo study another type of MWCNT (Graphistrength) showed irritating effects (chemosis, redness, iris lesions, corneal opacity) were observed. These were interpreted as secondary to abrasive (mechanical) action as no corneal opacification observed in BCOP (Bovine Corneal Opacity and Permeability) test. (; ) (; ) Rel 2; HE-CAM test, No TG, (WoE) Rel 1; OECD TG 405 Dermal Irritation VERY LOW: MWCNT is not irritating to skin Dermal Irritation No irritating or corrosive properties in dermal irritation (corrosion) test in vivo and reconstructed human skin (in vitro). No significant increase of IL-1alpha (marker of irritation) in human reconstructed epidermis in vitro 3 study reports (2006) () (; ) Rel 1; OECD TG 404 Rel 1; OECD TG 431 Rel 2;
Table S1. Analytes, parent and daughter mass ions, and quantification references. Target Analyte Typical Retention Time (min.) Parent Ion Mass Daughter Ion Mass Quantified Perfluorooctanoate (PFOA) 7.0 413 369 (169)1 13C2-PFOA Perfluorononanoate (PFNA) 7.4 463 419 13C5-PFNA Perfluorodecanoate (PFDA) 7.9 513 469 13C2-PFDA Perfluorohexanesulfonate (PFHxS) 7.2 399 80 (99/119)1 18O2-PFHxS Perfluorooctane sulfonate (PFOS) 8.2 499 80 (99)1 13C4-PFOS Surrogate Standard 13C2-Perfluorooctanoic acid (13C2-PFOA) 7.0 415 370 13C4-PFOA 13C5-Heptadecafluorononanoic acid (13C5-PFNA) 7.4 468 423 13C2-Perfluorodecanoic acid (13C2-PFDA) 7.9 515 470 18O2–Perfluorohexanesulfonate (18O2-PFHxS) 7.2 403 84 (103)1 13C4–Perfluorooctanesulfonate (13C4-PFOS) 8.2 503 80 (99)1 Recovery Standard 13C2-2H-Perfluoro-2-decenoic acid 7.3 459 394 External 13C4-Perfluorooctanoic acid (13C4-PFOA) 6.9 417 372 External 1 Alternate transition within brackets.
Diethyl phthalate 12.9 149.2→93.2 15 DEP 84-66-2 149.2→65.2 35 Diisobutyl phthalate 14.9 149→65 27 DiBP 84-69-5 149→93 20 Di-n-butyl phthalate 15.6 149.1→65 25 DnBP 84-74-2 149.1→93.1 25 Benzyl butyl phthalate 18.2 149.1→121 15 BBzP 85-68-7 149.1→65 10 Di(2-ethylhexyl) phthalate 19.3 279→149 2 DEHP 117-81-7 279→167 2 20.2 - 22.2 293→149 10 DINP 28553-12-0 293→85.1 5 Diisodecyl phthalate 21.7 – 23.2 307→149 5 DIDP 307→167 5 Di(2-propylheptyl) phthalate 21.5 307→149.1 5 DPHP 53306-54-0 307→167 5 acid diisononyl 20.2 - 21.8 155.2→81.1 1 DINCH 166412-78-8 281.2→155.1 2 Dimethyl 11.7 166.9→137.1 7.5 DMP-d4 93951-89-4 166.9→139 8 Dibutyl phthalate-3,4,5,6-d4 15.6 153.1→97.1 15 DBP-d4 93952-11-5 153.1→69 15
SI-2. Exposure assessment Table SI-2. Calculated daily intakes [ng/kg/d] in geometric means (ranges). Daily intake [ng/kg/d] DMP DEP DiBP DnBP BBzP DEHP DINP DIDP DPHP DINCH Inhalation (DIinh) 10.1 60.4 113 (0.65-758) 61.6 1.59 19.1 1.67 2.83 0.51 0.73 Dust ingestion (DIdust_i) 0.10 1.44 6.44 10.9 7.85 137 106 21.3 3.62 22.6 Dietary intake (DIdiet) 11.9 309 638 511 142 1256 163 209 27.5 215 Dermal uptake via hand (DIhw) 2.5×10-4 0.009 0.03 0.05 0.01 0.06 0.003 0.001 (2.3 × 10-5-0.02) 0.004 - Dermal uptake via dust (DIdermal_dust) 7.48×10-5 0.002 0.005 0.013 0.004 (1.96 × 10-4-0.08) 0.01 0.01 0.001 2×10-4 0.001 Dermal uptake via air (DIdermal_gas) 1.36×10-6 2.94×10-5 3×10-4 1.4×10-4 2.4 × 10-6 (7 × 10-8-2 × 10-5) 8.8×10-8 7.6× 10-10 (3× 10-8) 9.5× 10-7 7.2×10-5 0.002 Dermal uptake via PCPs (Ddermal_PCP) 0.33 39.9 0.07 0.1 0.03 0.11 - - 0.03 - Total (DItotal) 32.9 711 680 520 143 974 389 238 35.8 283 Giovanoulis et al. (2016) (DItotal_urine) 9.8 887 518 405 137 935 - - - 230
DINP 11000 various media and assumed contact factors - Europe (European Chemicals 2003) 10 ingestion (dust, diet), dermal uptake (consumer products, dust), inhalation - Europe (Wormuth et al. 2006) 670 (2000) ingestion (food, water, dust/soil), inhalation various various et al. 2011) 563 (1961) ingestion (food, dust), dermal uptake (hand wipes), inhalation 2013 Norway This study DIDP 10 ingestion (dust, diet), dermal uptake (consumer products, dust), inhalation - Europe (Wormuth et al. 2006) 295 (1834) ingestion (food, dust), dermal uptake (hand wipes), inhalation 2013 Norway This study DPHP 650 (1110) ingestion (diet) 2005 Germany (Fromme et al. 2007) 48.8 (289) ingestion (food, dust), dermal uptake (hand inhalation 2013 Norway This study DINCH 81000 ingestion (diet) 1995 Australia (NICNAS 2011) 366 (3620) ingestion (food, dust), dermal uptake (hand inhalation 2013 Norway This study
1.1 Synechococcus leopoldensis 2 Synechococcus sp. Sulfadiazine 0.14 Microcystis aeruginosa 7.2 Anabaena flos-aquae Sulfadimethoxine 480 Anabaena cylindrica >2000 Anabaena flos-aquae 1500 Anabaena variabilis 500 Microcystis aeruginosa 470 Microcystis wesenbergii >2000 Nostoc sp. 1100 Synechococcus leopoldensis 760 Synechococcus sp. Tetracycline 6.2 Anabaena CPB4337 0.09 Microcystis aeruginosa Thiamphenicol 1.3 Anabaena cylindrica 13 Anabaena flos-aquae 14 Anabaena variabilis 0.32 Microcystis aeruginosa 0.43 Microcystis wesenbergii 3.5 Nostoc sp. 0.36 Synechococcus leopoldensis 0.67 Synechococcus sp. Trimethoprim 112 Microcystis aeruginosa 253 Anabaena flos-aquae >200 Anabaena cylindrica >200 Anabaena flos-aquae 11 Anabaena variabilis 150 Microcystis aeruginosa >200 Microcystis wesenbergii 53 Nostoc sp. >200 Synechococcus leopoldensis >200 Synechococcus sp. 91.677 Anabaena flos-aquae >100 Synechococcus leopoldensis Tylosin 0.034 Microcystis aeruginosa 0.0842812 Anabaena flos-aquae 0.082449 Synechococcus leopoldensis Ofloxacin 0.016 Synechococcus leopoldensis 0.021 Microcystis aeruginosa S3. Cyanobacteria EC50 for antibiotics where more than one EC50 is available.